Volu-Sol Reagents Corp company manufactures diagnostic products for use by clinical laboratories; it also plans to provide personal emergency response products and services for consumers. The company's diagnostic business develops and manufactures chemical reagents, stains, and related equipment used by laboratories to detect certain properties in biological samples in fields such as hematology and microbiology. Volu-Sol's yet to be launched Insight Care services employ biosensors, cell phone, and GPS technology to remotely monitor a client's vital signs and provide assistance. Parent RemoteMDx is spinning off Volu-Sol to shareholders. Founded in 1991, ActiveCare (formerly Volu-Sol) has been aided by some of the world’s largest companies, including Matsushita Electric Works (Panasonic), which was not only an investor in the company, but has helped to shape its technologies.

Curis, Inc. company was founded in 2000 and is based in Cambridge, Massachusetts. Curis, Inc., a drug discovery and development company, focuses on the research and development of cancer therapeutics. The company, in collaboration with Genentech, is conducting a pivotal Phase II clinical trial on its lead molecule, GDC-0449 in advanced basal cell carcinoma patients, as well as various Phase II clinical trials in first-line metastatic colorectal cancer and in advanced ovarian cancer patients. It is also evaluating CUDC-101, a small molecule that is in a Phase I clinical testing and is designed to target histone deacetylase (HDAC), epidermal growth factor receptor (EGFR), and epidermal growth factor receptor 2 (Her2). In addition, Curis has a development candidate, CUDC-305, a Heat Shock Protein 90 (Hsp90) inhibitor.

Warner Chilcott plc company was founded in 1968 and is headquartered in Rockaway, New Jersey. Warner Chilcott PLC, formerly Warner Chilcott Limited, is a Bermuda-based specialty pharmaceutical company focused on the women’s healthcare and dermatology segments of the United States pharmaceutical market. It is an integrated company with internal resources dedicated to the development, manufacturing and promotion of its products. Its operations are carried through its wholly-owned subsidiaries in the United States, Puerto Rico, the Republic of Ireland and Northern Ireland. The Companies franchises are comprised of complementary portfolios of established branded and development-stage products. In October 2009, the Company announced it completed the acquisition of The Procter & Gamble Company’s global branded prescription pharmaceutical business.

Pain Therapeutics, Inc. was founded in 1998 and is based in San Mateo, California. Pain Therapeutics, Inc., a biopharmaceutical company, engages in the research and development of novel drugs. It has four drug candidates in clinical development programs, which include Remoxy, a novel controlled-release oral capsule form of oxycodone; PTI-202 and PTI-721, which are abuse-resistant forms of opioid drugs; and PTI-188 for the treatment of metastatic melanoma. The company is also developing a technology for the treatment of hemophilia in patients. Pain Therapeutics, Inc. has a strategic alliance with King Pharmaceuticals, Inc. for the development and commercialization of Remoxy, PTI-202, PTI-721, and other abuse-resistant opioid painkillers.

Johnson & Johnson Pharmaceutical Research & Development (J&JPRD) provides research and development support for the pharmaceutical business units of parent company, Johnson & Johnson. Its main research processes are divided into three franchises: central nervous system and internal medicine; biotech, immunology, and oncology (through J&J subsidiary Centocor); and virology (through Tibotec). The subsidiary -- which represents the largest segment of J&J's pharmaceutical R&D -- also does research in collaboration with other pharmaceutical organizations and biotech researchers, and has partnerships with the likes of Basilea Pharmaceuticals and Entelos.

Insys Therapeutics, Inc. company focuses on developing drugs for treating side effects of chemotherapy (such as nausea), as well as therapies for pain management and other central-nervous-system conditions. Its Dronabinol HG candidate, a generic capsule form of Marinol awaiting FDA approval, may treat chemotherapy-induced nausea and vomiting. The firm is also developing inhalation and room-temperature capsule and syrup forms of Dronabinol. In addition, its Fentanyl SL spray, delivered under the tongue for quick absorption, treats pain in cancer patients. All of the company's drug candidates are unique formulations of already-approved therapeutic ingredients.

Allon Therapeutics Inc. company's primary focus is on developing treatments for Alzheimer's and other neurodegenerative diseases that lead to memory loss and cognitive impairment. Its lead candidate AL-108 is a nasal spray that has shown some efficacy in clinical trials in treating the symptoms of patients with amnestic mild cognitive impairment, a precursor to Alzheimer's. Allon has collaborations with the National Institute on Aging, the Alzheimer's Disease Cooperative Study, the Institute for the Study of Aging, and the Tel Aviv University.

ZARS Pharma, Inc. operates as a specialty pharmaceutical company that focuses on developing and commercializing topically administered drugs using its proprietary drug delivery technologies, primarily in the area of pain management. It is developing a portfolio of proprietary products and product candidates based on its Controlled Heat-Assisted Drug Delivery and phase-changing cream technologies. The company’s products include Pliaglis, a topical anesthetic cream for dermal anesthesia prior to painful cosmetic procedures, such as laser surgery and dermal filler injections; and Synera, a topical patch for providing dermal analgesia for potentially painful superficial procedures, such as venous access procedures involving needles and immunization injections of children. Its products also comprise ThermoProfen, which is entering into Phase 3 clinical trials for the treatment of mild to moderate chronic pain associated with osteoarthritis of the knee; and Ketoprofen DuraPeel, a Phase 1 clinical trial product for the treatment of acute musculoskeletal pain resulting from soft tissue injuries, such as muscle strains, ankle sprains, and sports injuries. In addition, the company is developing the Alprazolam Patch, which is in Phase 1 clinical trial, for the treatment of panic disorder. The company was formerly known as ZARS, Inc. and changed its name to ZARS Pharma, Inc. in July, 2007. The company was founded in 1996 and is based in Salt Lake City, Utah.

International Brachytherapy (IBt) is planting the seeds of future health and vitality. IBt develops and markets interstitial implants -- commonly referred to as seeds -- used in brachytherapy to treat cancer. The radiotherapeutic implants are inserted inside or near cancerous tissue, delivering radioactive doses to tumors while sparing surrounding tissue. Founded in 1996, IBt operates from its Belgian headquarters as well as a US subsidiary, IBt Inc., and UK subsidiary IBt ltd. It also owns a majority stake in medical components provider Urorad GmbH.

Simcere Pharmaceutical Group was founded in 1995 and is headquartered in Nanjing, the People's Republic of China. Simcere Pharmaceutical Group is a manufacturer and supplier of branded generic pharmaceuticals in the Chinese market. The Company has introduced a generic anti-stroke medication under the brand name Bicun, a 5-FU sustained release implant under the brand name Sinofuan and an anti-cancer medication under the brand name Endu. It manufactures and sells 45 principal pharmaceutical products and is the distributor of three additional pharmaceuticals that are manufactured by independent third parties but marketed under its brand names. On May 5, 2008, it acquired 70% interest in Wuhu Zhong Ren Pharmaceutical Co., Ltd. (Wuhu Simcere Zhong Ren). On January 6, 2009, Simcere Pharmaceutical Group acquired the remaining 10% of interest of Shandong Simcere Medgenn Bio-Pharmaceutical Co., Ltd. (Shandong Simcere).

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.